Accentia Biopharmace (ABPI)

OTC Markets

Currency in USD

0.0001

0.0000(0.00%)

Closed·06/01

Day's Range

0.0001

52 wk Range

0.0000

0.0001

ABPI Income Statement

Featured here, the Income Statement (earnings report) for Accentia Biopharmace, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2003

30/09

2004

30/09

2005

30/09

2006

30/09

2007

30/09

2008

30/09

2009

30/09

2010

30/09

2011

30/09

2012

30/09

Total Revenues

aa.aa

15.92

10.56

5.36

3.96

4.05

Total Revenues Growth

aa.aa

-12.9%

-33.71%

-49.26%

-26.14%

+2.49%

Cost Of Revenues

aa.aa

9.68

7.86

2.92

2.52

2.81

Gross Profit

aa.aa

6.25

2.7

2.43

1.44

1.24

Gross Profit Growth

aa.aa

-34.59%

-56.82%

-9.76%

-41.01%

-13.34%

Gross Profit Margin %

aa.aa

39.24%

25.56%

45.46%

36.31%

30.7%

Other Operating Expenses, Total

aa.aa

33.03

9.53

5.64

22.61

12.78

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-30.65%	-71.14%	-40.78%	+300.53%	-43.46%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	8.92	1.32	1.3	2.23	5.24
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	24.11	8.21	4.34	20.38	7.55
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

-26.78

-6.83

-3.21

-21.17

-11.54

Operating Income Growth

aa.aa

+29.66%

+74.48%

+53.03%

-559.61%

+45.5%

EBIT Margin %

aa.aa

-168.16%

-64.74%

-59.93%

-535.19%

-284.58%

Net Interest Expenses

aa.aa

-28.06

-8.44

-16.66

-8.09

-7.91

Net Interest Expenses Growth

aa.aa

-45.16%

+69.93%

-97.46%

+51.42%

+2.29%

Interest Expense, Total

aa.aa

-28.06

-8.44

-16.66

-8.09

-7.91

Interest And Investment Income

aa.aa

Other Non Operating Expenses, Total

aa.aa

7.75

14.02

-28.19

1.08

1.4

EBT, Excl. Unusual Items

aa.aa

-47.09

-1.25

-48.06

-28.18

-18.04

Gain (Loss) On Sale Of Assets

aa.aa

-0.19

Other Unusual Items, Total

aa.aa

-16.07

-4.62

1.05

12.36

5.62

EBT, Incl. Unusual Items

aa.aa

-61.3

-7.4

-47.4

-15.83

-12.43

EBT, Incl. Unusual Items Growth

aa.aa

+20.41%

+87.93%

-540.84%

+66.61%

+21.48%

EBT, Incl. Unusual Items Margin

aa.aa

-384.96%

-70.07%

-884.97%

-400.09%

-306.52%

Income Tax Expense

aa.aa

Net Income to Company

aa.aa

-61.3

-5.72

-48.21

-15.65

-9.19

Minority Interest

aa.aa

0.51

0.45

0.41

4.1

4.87

Net Income

aa.aa

-60.79

-5.26

-47.8

-11.55

-4.32

Net Income Growth

aa.aa

+20.02%

+91.34%

-808.26%

+75.83%

+62.59%

Net Income Margin %

aa.aa

-381.74%

-49.86%

-892.41%

-292.05%

-106.61%

Preferred Dividend and Other Adjustments

aa.aa

2.77

2.8

2.33

Net Income to Common Excl. Extra Items

aa.aa

-63.56

-9.75

-49.32

-11.73

-7.56

Basic EPS - Continuing Operations

aa.aa

-1.38

-0.17

-0.85

-0.17

-0.09

Basic EPS - Continuing Operations Growth

aa.aa

+37.29%

+87.87%

-405.92%

+79.83%

+45.35%

Diluted EPS - Continuing Operations

aa.aa

-1.38

-0.17

-0.85

-0.17

-0.09

Diluted EPS - Continuing Operations Growth

aa.aa

+37.29%

+87.87%

-405.92%

+79.83%

+45.35%

Basic Weighted Average Shares Outstanding

aa.aa

45.9

58.03

58.05

68.44

80.74

Diluted Weighted Average Shares Outstanding

aa.aa

45.9

58.03

58.05

68.44

80.74

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-25.01

-6.35

-2.62

-20.61

-11.29

EBITDA Growth

aa.aa

+31.42%

+74.6%

+58.79%

-687.4%

+45.23%

EBITDA Margin %

aa.aa

-157.03%

-60.17%

-48.87%

-520.99%

-278.42%

EBIT

aa.aa

-26.78

-6.83

-3.21

-21.17

-11.54

* In Millions of USD (except for per share items)

NSE 30

5,064.19

-32.62

-0.64%

NSE All Share

138,780.55

-941.64

-0.67%

US 30

45,204.00

-91.7

-0.20%

US 500

6,424.40

+8.9

+0.14%

FTSE 100

9,116.69

-79.65

-0.87%

DAX

23,487.33

-550.00

-2.29%

South Africa Top 40

93,697.20

-574.16

-0.61%

Market Movers

Name	Last	Chg. %	Vol.
Guaranty Trust Holding	91.50	-0.54%	32.61M
Access Holdings	25.85	-1.34%	29.53M
Zenith Bank	64.60	+0.31%	18.97M
UBA	46.40	-1.80%	14.57M
Lafarge Africa	111.00	-9.76%	3.38M
MTN Nigeria	402.00	-7.59%	956.51K
Dangote Cement	510.00	-1.96%	710.63K

Name	Last	Chg. %	Vol.
Airtel Africa	2,541.50	+10.00%	50.00
Mecure Industries	21.45	+10.00%	157.02K
Skye Shelter Fund	331.60	+9.97%	10.69K
Ncr Nigeria	12.70	+9.96%	173.30K
SCOA Nigeria	7.240	+9.86%	127.41K
John Holt PLC	6.85	+8.73%	61.19K
Abbey Mortgage Bank	6.95	+6.92%	43.16K

Name	Last	Chg. %	Vol.
Npfmcrfbk	2.790	-10.00%	1.56M
UAC Of Nigeria	65.70	-10.00%	1.36M
Neimeth	5.94	-10.00%	1.08M
Total Nig	576.00	-10.00%	105.45K
Betaglas	437.40	-10.00%	223.02K
Aiico	3.42	-10.00%	21.80M
Geregu Power	1,027.40	-10.00%	2.13K

Trending Stocks

Name	Last	Chg. %	Vol.
MTN Nigeria	402.00	-7.59%	956.51K
Ellah Lakes	11.43	-9.93%	20.54M
Zenith Bank	64.60	+0.31%	18.97M
Custodian Allied	43.20	+6.01%	1.97M
Guaranty Trust Holding	91.50	-0.54%	32.61M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaa Aaaaa	5,389.90	+56.10%	8,413.63
Aaaaa Aaa	136.70	+42.24%	194.44
Aaaaa Aa	510.00	+38.70%	707.37
Aa Aa Aaaa A	1,791.10	+36.27%	2,440.73
Aaaaaaaaaaa Aaaaa	65.00	+35.97%	88.38
Aaaa A	576.00	+23.76%	712.86

Name	Last	Upside	Fair Value
Aaaaaaaaa Aaaaa	5,389.90	+56.10%	8,413.63
Aaaaa Aaa	136.70	+42.24%	194.44
Aaaaa Aa	510.00	+38.70%	707.37
Aa Aa Aaaa A	1,791.10	+36.27%	2,440.73
Aaaaaaaaaaa Aaaaa	65.00	+35.97%	88.38
Aaaa A	576.00	+23.76%	712.86

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Accentia Biopharmace (ABPI)

ABPI Income Statement

Trending Stocks